MedTrace Logo

Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction

NCT00430885 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-01-27

No results posted yet for this study

Summary

The instigators hypothesize that IVIG, given in the acute phase following MI in patients at risk for developing HF, will improve cardiac performance, and by attenuating cardiac remodeling in this phase, such therapy will prevent the development of chronic HF resulting in long term beneficial effect also after the therapy has been stopped.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Octagam (IVIG)

Intravenous immunoglobulin 0.4 g/kg given as infusion

Sponsors & Collaborators

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Lars Gullestad, MD, PhD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-05-31
Completion
2010-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430885 on ClinicalTrials.gov